Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03827655 · ClinicalTrials.gov registry record · Phase 2
A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery
A Phase 2 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 209
- Enrollment target
NCT03827655 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 209 participants.
The verdict
NCT03827655, a Phase 2 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 209 participants
- Enrollment target
Study Summary
The main aim of this study is to check for side effects from TAK-954 and whether it speeds up the recovery of gastrointestinal function after small-bowel or large-bowel resection surgery. Participants will be treated with TAK-954 before surgery and up to 10 days after surgery.
Interventions
- DRUG TAK-954
- DRUG TAK-954 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 2019-03-07 |
| Est. Completion | 2022-05-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03827655
The ClinicalTrials.gov registry entry for NCT03827655 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 209 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAK-954 is the first listed.
NCT03827655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03827655 about?
NCT03827655 is a clinical study titled "A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery". The main aim of this study is to check for side effects from TAK-954 and whether it speeds up the recovery of gastrointestinal function after small-bowel or large-bowel resection surgery. Participants will be treated with TAK-954 before surgery and up to 10 days after surgery.
What is the current status of trial NCT03827655?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 209 participants. The study started on 2019-03-07. Estimated completion is 2022-05-27.
What interventions are being tested in trial NCT03827655?
The interventions under investigation include: TAK-954 (DRUG), TAK-954 Placebo (DRUG).
Who is sponsoring clinical trial NCT03827655?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.